Table 2 Patient characteristics
Characteristic | Training cohort (n = 134) | Testing cohort (n = 33) |
|---|---|---|
Age (years), median (IQR) | 69 (65–72) | 68 (59–72) |
PSA (ng/mL), median (IQR) | 7.1 (5.1–12.7) | 8.1 (5.3–12.9) |
Clinical T stage, n (%) | ||
T1 | 66 (49.3) | 18 (54.5) |
T2 | 49 (36.6) | 10 (30.3) |
T3 | 17 (12.7) | 3 (9.1) |
Unknown | 2 (1.5) | 2 (6.1) |
Biopsy Gleason Grade Group, n (%) | ||
1 | 18 (13.4) | 3 (9.1) |
2 | 55 (41.0) | 15 (45.5) |
3 | 28 (20.9) | 7 (21.2) |
≥ 4 | 33 (24.6) | 8 (24.2) |
PI-RADS version 2 score, n (%) | ||
2 | 6 (4.5) | 2 (6.1) |
3 | 7 (5.2) | 0 (0.0) |
4 | 52 (38.8) | 16 (48.5) |
5 | 67 (50.0) | 15 (45.5) |
Not reported | 2 (1.5) | 0 (0.0) |
D’Amico risk group, n (%) | ||
Low-risk | 13 (9.7) | 3 (9.1) |
Intermediate-risk | 70 (52.2) | 19 (57.6) |
High-risk | 51 (38.1) | 11 (33.3) |
Pathological T stage, n (%) | ||
T2 | 85 (63.4) | 20 (60.6) |
T3 | 48 (35.8) | 13 (39.4) |
T4 | 1 (0.7) | 0 (0.0) |